Exhibitor - MorphoSys US, Inc. - Virtual Exhibit Hall - 2020 Mayo Clinic Oncology Review
COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff as we address the COVID-19 situation. Learn more about COVID-19 online education, resources, and live course cancellations through December 31, 2020.
For nearly 30 years, MorphoSys has helped to elevate the standard for how antibodies will be made in the future, with innovative technology that enables their use as research, diagnostic, and therapeutic tools. MorphoSys has one of the broadest pipelines in biotech.
100 distinct drugs currently in research and development.
25 therapeutic antibodies in clinical trials as potenial novel treatment options for severe and life-threating diseases.
Discover MORPHOSYS - See how MorphoSys is taking on some of the world's most serious diseases. MorphoSys is dedicated to bringing breakthrough medicines in oncology to the market to help address unmet needs for patients with B-cell malignancies.
Founded in 1992 in Germany, MorphoSys is dedicated to making exceptional, innovative biopharmaceuticals to help improve lives of patients suffering from serious diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. MorphoSys is headquartered in Planegg, Germany. In 2019, the US head office was established in Boston.
Connect with MorphoSys to learn more about our company.